BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Policy

  US FDA Accepts Regulatory Submission of New Drug Application for Selumetinib in Neurofibromatosis Type 1 (NF1) and Grants Priority Review

  AstraZeneca and Merck’s Selumetinib Would Become the First Medicine Indicated for the Treatment of Certain Pediatric Patients with NF1 Plexiform Neurofibromas if Approved

  November 14, 2019

   · 

  6 min read
• Business

  Fulcrum Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

  Initiated IND-enabling studies for FTX-6058 for the potential treatment of sickle cell disease and beta-thalassemia and announced pre-clinical data showing increase in HbF levels to ~30% of total hemoglobin

  November 14, 2019

   · 

  10 min read
• Business

  Eagle Pharmaceuticals Announces Departure of Douglas L. Braunstein from Board of Directors

  Eagle Pharmaceuticals, Inc. announced that Douglas L. Braunstein is stepping down from the Company’s Board of Directors, effective November 14, 2019.

  November 14, 2019

   · 

  3 min read